EurekAlert!

C-Path’s TRxA announces $1 million award for drug development project in type 1 diabetes

TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accelerator (TRxA) program, in partnership with The Leona M. and Harry B.
EurekAlert!

C-Path’s PKD outcomes consortium receives BAA Award for project to advance drug development tools for autosomal dominant tubulointerstitial kidney disease

TUCSON, Ariz., Sept. 19, 2024 — Critical Path Institute (C-Path) is thrilled to announce its Polycystic Kidney Disease Outcomes Consortium (PKDOC) has been awarded an Autosomal Dominant ...
BioWorld

Critical Path Institute funds development of QED-203 for advanced prostate cancer

Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and therapy-resistant prostate cancer. Based on research at the University of ...
News Medical

C-Path releases new publication on transforming drug development for neurological disorders

Critical Path Institute (C-Path) is pleased to announce the release of a new peer-reviewed publication, titled "Transforming Drug Development for Neurological Disorders: Proceedings from a ...
News Medical

C-Path’s TRxA awards $250,000 grant to develop novel treatment for type 1 diabetes

Critical Path Institute's ® (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment for type 1 diabetes (T1D). Kyle ...
FierceBiotech

EMA gives nod to Critical Path Institute's trial simulation platform for DMD

The European Medicines Agency sent a letter of support for Critical Path Institute’s efforts to establish a model-based clinical trial simulation platform that could help find new treatments for ...